Targets › CSF2RB
1 program from 1 company in 24 trials: 19 Phase 2, 5 Phase 1; Neurology, Oncology; next expected readout Apr 2028.
Cell surface receptor that plays a role in immune response and controls the production and differentiation of hematopoietic progenitor cells into lineage-restricted cells. Acts by forming an heterodimeric receptor through interaction with different partners such as IL3RA, IL5RA or CSF2RA. In turn, participates in various signaling pathways including interleukin-3, interleukin-5 and granulocyte-macrophage…. (UniProt, P32927)
Open in Phaseline: the race on CSF2RB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Y-mAbs Therapeutics | Sargramostim Granulocyte-macrophage colony-stimulating factor receptor agonist | CSF2RA, CSF2RB | Phase 2 | Neuroblastoma; Bilateral Breast Carcinoma; Neuroblastoma Recurrent; Alzheimer Disease … | Apr 2028 |
Neuroblastoma (2) Bilateral Breast Carcinoma (1) Neuroblastoma Recurrent (1) Alzheimer Disease (1) Solid Cancer (1) Transplant-Related Hematologic Malignancy (1) Cervical Cancer (1) Advanced Melanoma (1) Anatomic Stage IV Breast Cancer AJCC v8 (1) Oncology (1) Recurrent Osteosarcoma (1) Ganglioneuroblastoma, Nodular (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.